Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

University Hospital Del Mar, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Barcelona
Treatments:Biologic therapyHospital:University Hospital Del Mar
Drugs:Journal:Link
Date:Dec 2011

Description:

Patients:
This phase II study involved 38 patients with untreated urothelial cancer. The median patient age was 75 years and 79% were male.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that causes an inhibition of tumor growth.

Toxicity:
There were 2 treatment-related deaths due to heart failure and stroke. Grade 4 thrombocytopenia and grade 3 fatigue were also reported.

Results:
The median overall survival was 8.1 months.

Support:
This study was partially supported by Pfizer, the makers of sunitinib.

Correspondence: Dr. J. Bellmunt; email: [email protected]



Back